Norgine Celebrates EU CHMP Opinion on Mavorixafor for WHIM Syndrome Treatment Norgine B.V. recognizes a major regulatory milestone with CHMP's recommendation for mavorixafor, a treatment for WHIM syndrome in the EU. Final decision is anticipated soon.

Norgine Celebrates EU CHMP Opinion on Mavorixafor for WHIM Syndrome Treatment #Netherlands #Amsterdam #Norgine #Mavorixafor #WHIM_syndrome

Norgine Celebrates CHMP's Support for Mavorixafor in Treating WHIM Syndrome Norgine welcomes a positive opinion by the CHMP regarding mavorixafor's approval for WHIM syndrome in Europe, marking a significant milestone.

Norgine Celebrates CHMP's Support for Mavorixafor in Treating WHIM Syndrome #None #Norgine #Mavorixafor #WHIM_syndrome

Norgine Celebrates Positive CHMP Opinion for Mavorixafor Approval in the EU for WHIM Syndrome Norgine has welcomed the CHMP's positive recommendation for Mavorixafor to treat WHIM syndrome in the EU, paving the way for the first approved treatment.

Norgine Celebrates Positive CHMP Opinion for Mavorixafor Approval in the EU for WHIM Syndrome #Netherlands #Amsterdam #Norgine #Mavorixafor #WHIM_syndrome

Norgine Enthusiastically Welcomes CHMP's Positive Opinion for Mavorixafor Approval Norgine celebrates the positive CHMP opinion recommending approval for mavorixafor, marking an essential step for WHIM syndrome treatment in Europe.

Norgine Enthusiastically Welcomes CHMP's Positive Opinion for Mavorixafor Approval #None #Norgine #Mavorixafor #WHIM_syndrome

Norgine Celebrates Positive Recommendation for Mavorixafor Approval in Europe for WHIM Syndrome Norgine B.V. announces a positive recommendation from CHMP for mavorixafor's approval in Europe, a significant step for WHIM syndrome treatment.

Norgine Celebrates Positive Recommendation for Mavorixafor Approval in Europe for WHIM Syndrome #Netherlands #Amsterdam #Norgine #Mavorixafor #WHIM_syndrome